Fundz

Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics

PRIVATEAug 27, 2020

Round Type

Series A

AustinBiotechnologyHealth CareScience And EngineeringInternet Services

Description

Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD 55 million Series A financing round. The financing was co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co

Quick answer

Triumvira Immunologics Inc. raised an undisclosed amount in a Series A round, dated August 27, 2020. Triumvira Immunologics Inc. is based in Austin, Texas, United States.

How much did Triumvira Immunologics Inc. raise?
Triumvira Immunologics Inc. raised an undisclosed amount in a Series A round on August 27, 2020.
What does Triumvira Immunologics Inc. do?
At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease.
Where is Triumvira Immunologics Inc. based and how big is it?
Triumvira Immunologics Inc. is based in Austin, Texas, United States.
Who are the decision-makers at Triumvira Immunologics Inc?
Fundz holds 1 contact at Triumvira Immunologics Inc. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Internet Services around the same time

Companies in the same sectors as Triumvira Immunologics Inc. that raised within 45 days of this round, from Fundz verified event records.

  • SeLux Diagnostics, Inc. raised $814K (Seed) on October 1, 2020.
  • Bond Biosciences raised $4.5M on September 14, 2020.
  • Freenome raised $270M (Series C) on August 26, 2020.
  • Mythic Therapeutics raised $19M on August 14, 2020.
  • Mythic Therapeutics raised $4.7M on August 14, 2020.
  • Pictor Labs raised $617K (Seed) on October 7, 2020.

Who to call at Triumvira Immunologics Inc., and when

A new round usually means Triumvira Immunologics Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Triumvira Immunologics Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Triumvira Immunologics Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Triumvira Immunologics Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Triumvira Immunologics Inc.

Location

9433 BEE CAVE ROAD

Austin, Texas, United States

About

At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you. For more information about Triumvira career opportunities, please see our Careers web page at: https://triumvira.com/contact-us/careers/

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Triumvira Immunologics Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts21 people are listed at Triumvira Immunologics In…. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Triumvira Immunologics Inc.'s next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Triumvira Immunologics Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.